Last reviewed · How we verify
NeisVac-C® — Competitive Intelligence Brief
marketed
Meningococcal conjugate vaccine
Neisseria meningitidis serogroup C polysaccharide capsule
Immunology / Infectious Disease
Biologic
Live · refreshed every 30 min
Target snapshot
NeisVac-C® (NeisVac-C®) — Merck Sharp & Dohme LLC. NeisVac-C is a meningococcal serogroup C conjugate vaccine that stimulates the immune system to produce antibodies against Neisseria meningitidis serogroup C.
Comparator set (6 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| NeisVac-C® TARGET | NeisVac-C® | Merck Sharp & Dohme LLC | marketed | Meningococcal conjugate vaccine | Neisseria meningitidis serogroup C polysaccharide capsule | |
| Meningitec® | Meningitec® | GlaxoSmithKline | marketed | Conjugate vaccine | Neisseria meningitidis serogroup C polysaccharide capsule | |
| NeisVac C vaccine (12mth) | NeisVac C vaccine (12mth) | University of British Columbia | marketed | Meningococcal conjugate vaccine | Neisseria meningitidis serogroup C polysaccharide capsule | |
| Meningococcal C | Meningococcal C | Wyeth is now a wholly owned subsidiary of Pfizer | marketed | Conjugate vaccine | Neisseria meningitidis serogroup C polysaccharide capsule | |
| Prevenar and Meningitec | Prevenar and Meningitec | Wyeth is now a wholly owned subsidiary of Pfizer | marketed | Conjugate vaccine | Streptococcus pneumoniae polysaccharide capsule (Prevenar); Neisseria meningitidis serogroup C polysaccharide capsule (Meningitec) | |
| NeisVac-CTM | NeisVac-CTM | GlaxoSmithKline | phase 3 | Meningococcal conjugate vaccine | Neisseria meningitidis serogroup C polysaccharide capsule | |
| Neis-Vac-C | Neis-Vac-C | GlaxoSmithKline | phase 3 | Conjugate vaccine | Neisseria meningitidis serogroup C polysaccharide capsule |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Meningococcal conjugate vaccine class)
- GlaxoSmithKline · 8 drugs in this class
- CanSino Biologics Inc. · 3 drugs in this class
- Beijing Minhai Biotechnology Co., Ltd · 2 drugs in this class
- Novartis · 1 drug in this class
- Pfizer · 1 drug in this class
- University of British Columbia · 1 drug in this class
- International Vaccine Institute · 1 drug in this class
- Merck Sharp & Dohme LLC · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- NeisVac-C® CI watch — RSS
- NeisVac-C® CI watch — Atom
- NeisVac-C® CI watch — JSON
- NeisVac-C® alone — RSS
- Whole Meningococcal conjugate vaccine class — RSS
Cite this brief
Drug Landscape (2026). NeisVac-C® — Competitive Intelligence Brief. https://druglandscape.com/ci/neisvac-c. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing